Diabesity On Demand

Claiming CME Credit Requirements

The learner must complete all sections of the module including the assessment questions and the evaluation to receive credit. Partial credits will not be issued. Completion of this activity takes approximately 2.25 hours and can be completed in multiple sittings.

Upon successful completion of the assessments and evaluation, a certificate will be generated as a PDF for you to download.

All content is the copyrighted material of CineMed, Inc.

Release Date: September 1, 2020

Expiration Date: September 1, 2022

Overview

This activity explores the varying levels of obesity. This activity covers research on mechanisms of action of metabolic surgery, their RCTs that inform the question of where such operations fit in the overall treatment algorithm for type 2 diabetes and obesity, and how new data from those RCTs has led to policy changes pertaining to surgery that are evolving based on recommendations from the Diabetes Surgery Summit (DSS-2) consensus conference.

Target Audience

This activity is designed to meet the educational needs of Primary Care Physicians and Endocrinologists who regularly are asked to treat and manage overweight and obese patients.

Activity Goal

This activity is designed to address the following core and team competencies: Patient Care and Medical Knowledge.

Learning Objectives

• Discuss the weight-independent mechanisms mediating remission of type 2 diabetes after selected types of bariatric/metabolic surgery.
• Describe recent Level 1 evidence from randomized clinical trials directly comparing surgical vs. non-surgical approaches to diabetes care, including among patients with a baseline BMI <35 kg/m².
• Identify new policy changes from the 2nd Diabetes Surgery Summit and the American Diabetes Association advocating consideration of metabolic surgery to treat patients with inadequately controlled type 2 diabetes and a BMI as low as 30 kg/m², or 27.5 kg/m² for Asians.

Disclosure

The provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. - All provider employees and activity planners in control of content have indicated that they have no relevant financial relationships to disclose.

Faculty Disclosure Summary

Dana Portenier, MD, FACS, FASMBS: Medtronic - Speaker/Research Grant; Gore - Education Grant/ Speaker; Teleflex - Consultant/Research Grant; Da Vinci -Consultant/Research Grant; Levita Magnetics - Advisory Board Changzhou Panda Medical Co. Ltd -Ownership; Novo Nordisk - Consultant

Kelli Friedman: Medtronic - Speaker/Research Grant; Gore - Education Grant/ Speaker; Teleflex - Consultant/Research Grant; Da Vinci -Consultant/Research Grant; Levita Magnetics - Advisory Board; Changzhou Panda Medical Co. Ltd - Ownership; Novo Nordisk - Consultant

David Cummings: P.I. on the COSMID trial funded by Johnson & Johnson; ARMMS-T2D Trial funded by NIH, Johnson & Johnson, and Covidien

Deborah Horn, DO, MPH, MFOMA: Novonordisk - Consultant, Research, Speaker; Bausch/Valeant - Consultant; Medtronic - Consultant

Lillian Craggs-Dino, DHA, RDN, LDN, CLT: Bariatric Fusion - Advisory Board

Non-Endorsement Statement

The provider verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. The provider does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization.

Industry Support

This activity is supported by an educational grant from Medtronic.